Fig. 1: Effects of Erk1/2i + CDK4/6i on MM cell lines and HD-PBMC.
From: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
A Box plots showing ERK1/2 and CDK4/6 gene expression values in CD138 + PC from monoclonal gammopathy of undetermined significance (MGUS; n = 11), multiple myeloma (MM; n = 133), plasma cell leukemia (n = 9; PCL), and NPC (healthy donors), from dataset GSE13591. The error bars show the standard deviation. Horizontal bars indicate the mean value. The x-axis shows the samples analyzed, and the y-axis displays the expressions at log2 fold. These analyses confirmed significant (0.05 > P < 0.3E-0.07) overexpression of ERK1/2, CDK4 and CDK6 transcripts in clonal PCs. B Efficacy studies in MM cell lines (H929, MM.1Smch (mCherry (red fluorescent protein)), MM1R, AMO1, KMS12, RPMI8226, OPM2, and U266) and HD PBMCs at different time points after LY3214996 (Erk1/2i) and LY2835219 (CDK4/6i) treatment at different concentration ranges are shown on the x-axis; Cell viability (means and standard deviations) is shown as percentage of control untreated cells. C Determination inhibitory potency (IC50) of Erk1/2i for MM. MM (H929-NRAS, MM.1S, RPMI8226. OPM2 and U266) cell lines were treated with DMSO or ERK1/2i (0-15uM MM cell lines in RPMI medium with 0.1% DMSO and 10% FBS for 24–72 h. The concentration of drug that caused 50% inhibition of cell proliferation (IC50) relative to DMSO control was determined by non-linear regression using Prism, version 8.
